Publications by authors named "M Garces-Sanchez"
Background: The majority of respiratory syncytial virus (RSV) infections in young children are managed in primary care, however, the disease burden in this setting remains poorly defined.
Methods: We did a prospective cohort study in primary care settings in Belgium, Italy, Spain, the Netherlands, and the UK during the RSV seasons of 2020-21 (UK only; from Jan 1, 2021), 2021-22, and 2022-23. Children aged younger than 5 years presenting to their general practitioner or primary care paediatrician with symptoms of an acute respiratory tract infection were eligible for RSV testing.
Article Synopsis
- This study evaluates nirsevimab, a monoclonal antibody, for preventing respiratory syncytial virus (RSV) infections in infants under ten months in Spain.
- It involved a large immunization campaign where infants born after April 1, 2023, received nirsevimab either at birth or through a catch-up program.
- Results showed nirsevimab had an overall effectiveness of 75.8% and 80.2% in the catch-up group, highlighting its role in reducing RSV-related illnesses in primary care settings.
Introduction: Epilepsy surgery is the only curative treatment for patients with drug-resistant focal epilepsy. Stereoelectroencephalography (SEEG) is the gold standard to delineate the seizure-onset zone (SOZ). However, up to 40% of patients are subsequently not operated as no focal non-eloquent SOZ can be identified.
View Article and Find Full Text PDF